[Insulin lispro].
The results of the clinical studies of insulin lispro carried out in Japan to confirm the pharmacodynamics, pharmacokinetics, efficacy and safety, which were recently released were summarized in this article. When compared to human regular insulin, single subcutaneous injection to healthy persons showed that insulin lispro was adsorbed and disappeared more rapidly in blood stream and blood lowering action revealed more early. The potency of hypoglycemic action was stronger. Long-term multicenter, randomized, comparative, parallel, open-label study to diabetic patients of both type 1 and type 2 by multiple injection method showed that insulin lispro resulted in the significant improvement of 2 hour-postprandial blood glucose level 12 and 24 weeks after the initiation of treatment. HbA1c level did not change between two groups during the study. Insulin lispro did not give any adverse effects during 48 week-study. These studies support the conclusion that insulin lispro is useful and effective in the treatment of diabetes as a short-acting insulin.
Matsuda
A
A
Utsunomiya Chyuo Hospital.
D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D061268:Insulin Lispro; D015337:Multicenter Studies as Topic; D019518:Postprandial Period; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro